12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

Prev AbR LLC, Synthetic Biologics deal

Synthetic will acquire from Prev products targeting beta-lactamase to prevent Clostridium difficile infection. Prev received $100,000 up front, and will receive $135,000 in cash and 625,000 Synthetic shares upon closing of the...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >